Eloralintide for Osteoarthritis

(ENLIGHTEN-4 Trial)

This trial explores the effectiveness and safety of Eloralintide for individuals who are overweight or obese and suffer from knee osteoarthritis with pain. Participants will receive either Eloralintide or a placebo (a substance with no active drug) to compare effects. It is ideal for those with a BMI of 27 or higher who have struggled to lose weight and experience knee issues such as morning stiffness or a crackling sound. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants an opportunity to contribute to potentially groundbreaking treatment advancements.

The trial does not specify if you need to stop taking your current medications. However, you cannot have taken any weight loss medications or remedies in the 90 days before screening.

Research shows that Eloralintide has been tested in earlier human studies. Researchers closely monitored the safety of Eloralintide and carefully noted any unwanted side effects. Most participants handled the treatment well. Common side effects included mild reactions at the injection site and some cases of nausea. Serious side effects were not commonly reported, suggesting that Eloralintide is generally well-tolerated. This information provides a positive view of the safety of Eloralintide for those considering joining a clinical trial.¹²³⁴⁵

Eloralintide is unique because it brings a fresh approach to treating osteoarthritis by being administered subcutaneously, which might offer more targeted relief. Current standard treatments often involve oral medications like NSAIDs or corticosteroid injections. Unlike these, Eloralintide's subcutaneous delivery could potentially reduce systemic side effects and provide more localized action. Researchers are excited about Eloralintide because it may offer a novel mechanism of action that specifically targets the inflammatory processes in osteoarthritis, paving the way for more effective symptom management.

Research shows that Eloralintide, a medication targeting specific receptors, may help reduce knee pain in people with osteoarthritis (OA) who are overweight or obese. Previous studies found that Eloralintide led to significant weight loss, with participants losing up to 11% of their body weight after 12 weeks of treatment. This weight loss likely reduces stress on the knees, potentially easing OA pain. Although direct evidence on pain reduction in OA is limited, the promising weight loss effects suggest potential benefits for knee health. Early findings support further research into its effectiveness for relieving osteoarthritis pain. Participants in this trial will receive either Eloralintide or a placebo to evaluate its impact on OA symptoms.¹²³⁵⁶